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CCl4HGF/c-Met signaling plays a pivotal role in hepatocyte survival and tissue remodeling during liver regeneration.
HGF treatment accelerates resolution of ﬁbrosis in experimental animal models. Here, we utilized Metﬂ/ﬂ;Alb-
Cre+/− conditional knockout mice and a carbon tetrachloride(CCl4)-induced liver ﬁbrosis model to formally ad-
dress the role of c-Met signaling in hepatocytes in the context of chronic tissue injury. Histological changes dur-
ing injury (4 weeks) and healing phase (4 weeks) weremonitored by immunohistochemistry; expression levels
of selected key ﬁbroticmoleculeswere evaluated bywestern blotting, and time-dependent global transcriptomic
changes were examined using a microarray platform. Loss of hepatocyte c-Met signaling altered hepatic micro-
environment and aggravated hepatic ﬁbrogenesis. Greater liver damage was associated with decreased hepato-
cyte proliferation, excessive stellate cell activation and rapid dystrophic calciﬁcation of necrotic areas. Global
transcriptome analysis revealed a broad impact of c-Met on critical signaling pathways associated with ﬁbrosis.
Loss of hepatocyte c-Met caused a strong deregulation of chemotactic and inﬂammatory signaling (MCP-1,
RANTES, Cxcl10) in addition to modulation of genes involved in reorganization of the cytoskeletal network
(Actb, Tuba1a, Tuba8), intercellular communications and adhesion (Adam8, Icam1, Itgb2), control of cell prolifer-
ation (Ccng2, Csnk2a, Cdc6, cdk10), DNA damage and stress response (Rad9, Rad52, Ercc4, Gsta1 and 2, Jun). Our
study demonstrates that deletion of c-Met receptor in hepatocytes results in pronounced changes in hepaticme-
tabolism and microenvironment, and establishes an essential role for c-Met in maintaining the structural integ-
rity and adaptive plasticity of the liver under adverse conditions.
Published by Elsevier B.V.1. Introduction
Liver ﬁbrosis occurs as a consequence of most chronic liver dis-
eases [1]. Progressive accumulation of extracellular matrix (ECM) in
response to excessive liver damage destroys tissue architecture and
impairs liver function. Most common etiological factors in western
countries are HCV, excessive alcohol consumption and development
of non-alcoholic fatty liver (NAFLD)/non-alcoholic steato-hepatitis
(NASH) [2,3]. These diseases, particularly NASH, affect more thanFLD/NASH, non-alcoholic fatty
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orgeirsson).
.V.100 million patients in the USA alone and cause a rising incidence
worldwide [4]. Liver ﬁbrosis is generally a slow process [5] inﬂuenced
by a variety of genetic factors leading to a broad spectrum of individ-
ual responses to the same etiological agent [6]. Despite increasing in-
terest and substantial progress in unraveling the contributing genetic
factors and associated key pathways (e.g. TGF-β) [7], the mechanisms
of ﬁbrogenesis remain poorly understood [8].
HGF/c-Met signaling is of major importance for liver development
and regeneration with a mitogenic, motogenic and morphogenic ef-
fect on hepatocytes, hepatic progenitor cells and nonparenchymal
liver cells [9,10]. HGF/c-Met signaling is also known to be involved
in pathogenesis as well as resolution of ﬁbrosis [11]. Administration
of HGF has been shown to reverse ﬁbrosis and decrease hepatocyte
apoptosis in a rat model of cirrhosis [12]. Additionally, activation of
HGF/c-Met signaling reduced levels of TGF-β, one of the key media-
tors of ﬁbrogenesis, in several experimental models [13]. Besides
the protective effects on hepatocytes, HGF administration caused ap-
optosis of activated hepatic stellate cells (HSC) and increased matrix
metalloproteinase (MMP) expression [14–16]. However, despite the
well documented protective role of HGF against ﬁbrogenesis,
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chronic liver damage is less known.
Given the essential role of HGF in liver homeostasis [10,17], in
this study we used conditional mouse genetics and comprehensive
gene expression proﬁling to deﬁne the molecular mechanisms un-
derlying the anti-ﬁbrotic effects of HGF/c-Met signaling in hepato-
cytes. Our results show that mice with a targeted inactivation of
the c-met gene in hepatocytes were more prone to liver damage
and to development of ﬁbrosis when challenged with CCl4. The
proﬁbrotic effects of c-Met deﬁciency were mediated by increased
expression of numerous inﬂammatory cytokines and oxidative
stress response genes in addition to disruption of structural integ-
rity and lack of compensatory regeneration. These studies support
an essential role for HGF/c-Met in ﬁbrogenesis and highlight a
broad range of c-Met protective effects in chronic ﬁbrotic liver
diseases.
2. Materials and methods
2.1. Animal studies
Metﬂ/ﬂ/Alb-Cre+/− and control Metwt/wt;Alb-Cre+/− mice were
generated and genotyped as described [10]. Eight to nine week-old
female mice received multiple i.p. injections of CCl4 (1 μl/g) in miner-
al oil (Sigma) twice a week for a period of 4 weeks (referred to as in-
jury phase) and monitored for another 4 weeks (referred to as
healing phase) (n=5 per genotype/time point) (Supplemental Fig.
S1). Mice were sacriﬁced each week, 2 days after the last injection.
For acute studies, mice were injected once with CCl4 (1 μl/g). Blood
was collected from orbital venous plexus of 3 mice under isoﬂurane
anesthesia before sacriﬁce, and the serum levels of albumin and as-
partate aminotransferase (AST) were measured by Analytics, Inc.
(Gaithersburg, MD). Animals were housed in an AAALAC facility and
cared for in accordance with the guidelines from the Animal Care
and Use Committee at the National Cancer Institute, NIH.
2.2. Histology, immunhistochemistry and BrdU labeling
Livers were ﬁxed in 10% formalin overnight, embedded in parafﬁn
and stained with H&E for routine histopathological examination, or
processed for αSMA (Dako (M0851), 1:200), F4/80 (eBioscience
(14-4801-81), 1:25) and CD47 (BD (555297), 1:100) immunohisto-
chemistry. For the detection of BrdU incorporation, livers were ﬁxed
in alcoholic-formalin for 4–6 h, and 5-μm parafﬁn sections were
stained with ant-BrdU (1:100; Becton Dickinson). At least 1,000
cells were counted per animal to determine the percentage of
BrdUrd-positive cells (labeling index).
2.3. Liver collagen content
Collagen content was assessed by morphometric analysis of Sirius
red staining of liver sections and by hydroxyproline concentration
[18]. The area of positive Sirius red staining was measured using a
computerized analysis method. Hydroxyproline content was quanti-
ﬁed colorimetrically from 0.1 g liver samples. The extent of liver ﬁ-
brosis was determined on liver sections stained with Picrosirius red
solution using ImageJ sofware. Histological grading of the ﬁbrosis
was determined using a scoring system adapted from Scheuer et al.
[19] (0, none; 1, enlarged, ﬁbrotic central vein tracts; 2, pericentral
septa, intact architecture; 3, ﬁbrosis with architectural distortion, no
cirrhosis; and 4, probable or deﬁnite cirrhosis).
2.4. Western blotting
Whole cell lysates (100 μg) were prepared from frozen tissues
using T-PER Tissue Extraction Buffer (Pierce) containing CompleteProtease Inhibitor Cocktail (Roche), separated by SDS-PAGE and
transferred onto Invitrolon PVDF (Invitrogen). Membranes were
probed with speciﬁc antibodies against TGF-β1 (Santa Cruz (sc-
146), 1:500), HGF-α (Santa Cruz (sc-1358), 1:200), CTGF (Santa
Curz (sc-14939), 1:200), a-SMA (Dako (M0851), 1:200), Cd47 (BD
(555297), 1:1000), Nrf2 (Santa Cruz (sc-722), 1:200), Keap1 (Santa
Cruz (sc-33569), 1:200), γ-GCS (Santa Cruz (sc-22775), 1:500), p47
(Santa Cruz (sc-7660), 1:500), Nox2 (gp91 phox, Santa Cruz (sc-
5826) 1:500), Nox4 (Santa Cruz (sc-21860), 1:200). Immune com-
plexes were detected using the enhanced chemiluminescence system
(Pierce).2.5. Lipid peroxidation assay
Lipid peroxidation was assayed by the production of thiobarbituric
acid-reactive components (TBARS) using spectrophotometry as de-
scribed by Buege and Aust [20].2.6. GSH determination
GSH and GSSG content was determined by HPLC as described in
[21].2.7. Gene expression microarray and data analysis
Total RNAwas isolated from frozen liver tissue with TRIzol reagent
(Invitrogen) or RNeasy Kit (Qiagen) according to the manufacturer's
instructions. Whole liver transcriptomics were analyzed using Illu-
mina Bead Chip Mouse Ref8-v2 arrays containing 25,600 well-
annotated RefSeq transcripts, over 19,100 unique genes as described
[22]. Four animals of each genotype were used for each time point
(1 d, 1 week, 2 weeks and 3 weeks). Gene expression values were
normalized by quantile normalization across all samples, referenced
to the corresponding untreated livers and log2 transformed. The
microarray datasets have been deposited to Gene Expression Omni-
bus database (http://www.ncbi.nlm.nih.gov/geo, accession number
GSE25583).
Isolated hepatocyte microarrays were performed on Mm_MEEBO-
v1p6 containing 37,099 probes printed at the Advanced Technology
Center (NCI/NIH) following a dye-swapping design as described
[23]. Hepatocytes were isolated 2 days after the second exposure to
CCl4 (1 week time point) from three mice for each experiment per-
formed in duplicates. Total RNA pooled from ten B6/129 strain
mouse livers was used as universal hybridization reference. Arrays
were scanned with a GenePix 4000A scanner (Axon Instruments,
Ltd.) to achieve an optimal signal intensity at both channels with
b1% saturated spots. The image spots with a diameter of b10 or
>300 μm or a signal intensity below background intensity for any of
the two ﬂuorescent channels were excluded. After excluding the in-
valid features, all arrays were normalized to the 50th percentile of
the median signal intensity using the mAdb data analysis suite.1.
Unsupervised cluster analysis was done with the Cluster and Tree-
View programs Michael Eisen Laboratory, Lawrence Berkeley Nation-
al Laboratory and University of California, Berkeley; http://rana.lbl.
gov/eisen/)). The 2-factor time course analysis tool of the BRB Array-
Tools V3.3.0 software package (Biometric Research Branch, National
Cancer Institute) was used for the analysis of time course expression
data. All tests are performed at a false discovery rate (FDR) threshold
of 0.05. Only genes with a fold change ≥2 were included in the ana-
lyses. Selected genes were validated using RT-qPCR (Supplemental
Fig. 4). Functional classiﬁcation and network analysis were performed
using Ingenuity Pathway Analysis (Ingenuity Systems Inc.) and the
GeneGo pathways analysis (Pathway Analysis MetaCore - GeneGo
Inc., St. Joseph, MI) tools.
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Statistical analysis was performed using Student's t-test. P-values
≤0.05 were considered statistically signiﬁcant. Results are presented
as mean±SD or mean±SEM as indicated.
3. Results
3.1. c-Met deletion in hepatocytes results in increased activity of stellate
cells and rapid progression of ﬁbrosis
To induce liver ﬁbrosis, we used a model of toxic liver injury with
repeated injections of CCl4 and compared the cellular, biochemical
and molecular responses in c-Met deﬁcient and control mice. Mice re-
ceived biweekly injections of CCl4 during 4 weeks and were followed
for 4 consecutive weeks (Supplemental Fig. S1).
We conﬁrmed that the basal expression of Cyp2e was comparable
between genotypes (Supplemental Fig. S2). After a challenge with a
single dose of CCl4, both the serum AST levels and areas of necrosis
increased more rapidly and reached higher levels in mutant livers,
although the differences did not reach a statistical signiﬁcance. c-
Met deﬁcient livers were capable of clearing necrotic tissue and to
repopulate the affected area albeit after some delay suggesting that
compensatory liver regeneration was not signiﬁcantly affected
(Supplemental Fig. S2, A–C) [10]. The latter appears to contradict
the mitogenic role of HGF during acute liver injury with CCl4
[24,25]. This seeming discrepancy may be attributed to the differ-
ences between the employed experimental models. In mice with a
targeted disruption of c-Met expressing the Cre-recombinase under
the control of Alb-Cre promoter, the gradual c-met gene deletion isFig. 1. Reduced DNA replication and impaired functional performance during CCl4-induced ﬁ
The data are presented as means±SE (n=5). (B) BrdU labeling index. Mice received 150 μg
of at least 1000 hepatocytes per animal and expressed as percent of BrdU-positive cells. Th
nostaining after two injections of CCl4. (D) Changes in albumin serum levels. The data are ptaking place after birth and is completed by 6 weeks of age
[10,26,27] causing an adaptive up-regulation of alternative survival
and proliferating signaling [21,23,28]. However, upon a greater
CCl4-induced liver injury, e.g. caused by phenobarbital pre-
treatment [10] or chronic toxic liver insult [29], Metﬂ/ﬂ;Alb-Cre+/−
hepatocytes were unable to maintain an adequate level of prolifera-
tion. The decrease in proliferation was paralleled by a considerable
decrease in serum albumin levels (Fig. 1A–D) thus highlighting the
non-redundant role of HGF/c-Met signaling for efﬁcient regeneration
of the diseased liver.
When challenged with repeated CCl4 injections, the mutant livers
rapidly became stiff and acquired irregular surface characteristic of ﬁ-
brotic liver disease (Fig. 2A). Already after 2 injections of CCl4, the
concentration of hydroxyproline, a major component of collagen,
was increased in c-Met deﬁcient livers about 2-fold (Pb0.05) as com-
pared to similarly treated Metwt/wt;Alb-Cre+/− controls (Fig. 2B).
Quantiﬁcation of Sirius red staining of collagen ﬁbers and grading of
ﬁbrosis using a scoring system adapted from Scheuer et al. [19] con-
ﬁrmed a rapid accumulation of extracellular matrix (ECM) (Fig. 2C–
E). Histologically, mutant livers showed a quick activation of hepatic
stellate cells, a key contributor to ﬁbrosis [30], and expressed consid-
erably higher levels of α-SMA, a marker of activated stellate cells, as
shown by immunohistochemistry and Western blotting (Fig. 2, F
and G). Furthermore, resolution of ﬁbrosis induced by chronic CCl4
exposure occurred slower in knockout mice. The ﬁbrotic septa and
uneven liver surface were still visible after 4 weeks of healing in
Metﬂ/ﬂ;Alb-Cre+/− mice (Fig. 2A). In contrast, control mice showed
only a rudimentary collagen accumulation which did not result in dis-
tortion of lobular architecture and regressed rapidly during the heal-
ing phase.brosis in Metﬂ/ﬂ;Alb-Cre+/−mice . (A) Time course changes in liver-to-body mass ratio.
/g of BrdU 2 h before tissue collection. The labeling index was determined after scoring
e data are presented as means±SE (n=5). (C) Representative images of BrdU immu-
resented as means±SD (n=4). *Pb0.05; **Pb0.01; ***Pb0.001.
Fig. 2. Genetic loss of c-Met receptor in hepatocytes results in excessive HSC activation and progression of CCl4-induced ﬁbrosis. (A) Macroscopic appearance of liver. (B) Hydroxy-
proline content. Values are mean±SE (n=5). (C) Representative images of Sirius red staining during injury (3 w) and healing phase (8 weeks) in Metﬂ/ﬂ;Alb-Cre+/− and Metwt/wt;
Alb-Cre+/− mice. (D) Quantiﬁcation of Sirus red-positive areas using NIH ImageJ software. The data are presented as means±SE (n=5). (E) Histological grading of ﬁbrosis
(adapted from Scheuer et al. [19]). The data are presented as means±SE (n=5). (F) Representative images of α-SMA immunohistochemistry during injury phase (3 weeks).
(G) Western blotting of whole cell lysates prepared from Metﬂ/ﬂ;Alb-Cre+/− and Metwt/wt;Alb-Cre+/− livers using anti-α-SMA. β-Actin served as a loading control. * Pb0.05;
**Pb0.01.
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The hallmark feature of CCl4-induced liver ﬁbrosis in c-Met deﬁ-
cient mice was disruption of coordinated hepatic wound-healing re-
sponse leading to chronic injury. While control livers showed
repetitive cycles of hepatic damage and repair, c-Met-deleted livers
displayed persistence of centrolobular injury a long time after the
ﬁrst CCl4 administration (Supplemental Fig. S3A–G). The repair im-
pediment cannot be explained only by a diminished proliferativeresponse (Fig. 2) but rather due to changes in the necrotic milieu af-
fecting the dynamics of healing. Histological markers of unresolved
healing in Metﬂ/ﬂ;Alb-Cre+/− mice were rapid dystrophic calciﬁca-
tion of necrotic areas and massive ‘foreign body reaction’ as mani-
fested by von Kossa staining and accumulation of multinucleated
giant cells. Multinucleated cells were positive for F4/80, a marker of
inﬁltrating macrophages, and expressed CD47, known to contribute
to macrophage fusion thought to increase the capacity to remove or
sequester necrotic material (Fig. 3, B and C) [31]. Together these
Fig. 3. Abnormalities of liver remodeling after chronic injury with CCl4 caused by hepato-
cyte c-met deletion. (A) Dystrophic calciﬁcation of pericentral necrotic areas in Metﬂ/ﬂ;
Alb-Cre+/− livers. Van Kossa staining, 2 weeks of injury. Original magniﬁcation, ×200.
(B) Representative images of F4/80 immunhistochemistry (upper and middle panels)
and F4/80 immunoﬂuorescence (bottom panels). Inset shows a multinucleated F4/80-
positive cell at higher magniﬁcation. (C) Expression of Cd47 in multinucleated giant
cells present in Metﬂ/ﬂ;Alb-Cre+/− livers at 2 weeks of CCl4-induced injury) (white
arrows). Metwt/wt;Alb-Cre+/− livers displayed only weak Cd47 positivity detected in a
few mononucleated cells within the inﬂammatory inﬁltrate (arrowhead). Nuclei were
counterstained with DAPI. Scale bars, 50 μM (B) and 20 μM (C). pv, portal vein; cv, central
vein.
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compromised in c-Met deﬁcient livers which could contribute to the
delayed resolution of inﬂammation and ﬁbrosis.
3.3. Loss of c-Met aggravates ﬁbrosis through mechanisms dependent on
oxidative stress
Oxidative damage is a well established component of CCl4-induced
hepatic injury. In particular, mediators released from damaged hepato-
cytes, such as reactive oxygen species (ROS) and lipid peroxidation
products have been identiﬁed as strong inducers of HSC activation
[1,32–34]. Previously, we have shown that loss of c-Met receptor in he-
patocytes creates a prooxidant state which is compensated by constitu-
tive activation of key transcription factors protecting against oxidative
and xenobiotic stress, including nuclear factor (erythroid-derived 2)-
like 2 (Nrf2) and NF-kB [21,23]. Furthermore, although hepatocyte
c-Met conditional knockout mice did not exhibit an obvious pathology,
these mice were more susceptible to increased oxidative load, e.g.
caused by Fas or DEN exposure [10,21,28].
To address the possibility whether the loss of c-Met receptor in
hepatocytes may contribute to ﬁbrosis through modulation of ROS
generation, we ﬁrst measured the rate of production of thiobarbituric
acid-reactive substances (TBARS). The lipid oxidation was consider-
ably increased in Metﬂ/ﬂ;Alb-Cre+/− mice, both untreated and chal-
lenged with CCl4 (Fig. 4A). In addition, we found a statistically
signiﬁcant decrease in the GSH/GSSG ratios reﬂecting a diminished
capacity of the major antioxidant defense system in the absence of
hepatocyte c-Met (Fig. 4B). Furthermore, while control mice showed
a strong upregulation of Nrf2 which was paralleled by a decreased ex-
pression of Keap1, a repressor of Nrf2 activity, hepatocyte c-Met
knockout mice displayed reduced protein levels of Nrf2 as well as
SOD1 and γ-GCS, two well known targets of Nrf2 signaling (Fig. 4C).
Conversely, the expression of several components of ROS generating
NADPH oxidase complex, in particular p47 and Nox4, were increased
in c-Met deﬁcient livers as compared to CCl4-treated controls
(Fig. 4C). Western blotting conﬁrmed that the protein levels of TGF-
β, one of the major proﬁbrotic factors as well as the duration of acti-
vation were increased in Met-deﬁcient livers, while the expression
levels of HGF and CTGF were comparable in Metﬂ/ﬂ;Alb-Cre+/− and
control mice subjected to multiple CCl4 injections (Fig. 4D). Consis-
tent with previous reports, an initial increase in Hgf mRNA levels in
response to the CCl4-mediated liver injury was followed by a rapid
decline (not shown) possibly due to TGF-β upregulation [35–37]. To-
gether, these results suggest that a greater CCl4-mediated liver toxic-
ity in hepatocyte speciﬁc c-Met knockout livers may be related to
increased oxidative stress.
3.4. Transcriptomic changes during ﬁbrogenesis
To further attribute the involved functional processes directly to c-
Met deﬁciency in hepatocytes, we performed microarray analysis of
hepatocytes isolated from Metﬂ/ﬂ;Alb-Cre+/− and Metwt/wt;Alb-
Cre+/− livers two days after the second exposure to CCl4, a time
point of prominent impairment of hepatocyte function and rapid ac-
tivation of stellate cells in c-Met deﬁcient livers (Figs. 1D and 2, F
and G). An analysis using complementary DNA microarrays identiﬁed
406 transcripts which were differentially (175 down; 231 up)
expressed in c-Met knockout hepatocytes with more than 2-fold ex-
pression changes (Bootstrap t-test with a P-value cut-off of 0.01).
These genes efﬁciently separated two genotypes in the cluster ana-
lyses (Fig. 5A). The major associated functional networks were cen-
tered on plethora of genes important for immune response and
inﬂammation (Fig. 5B). Signiﬁcantly, exposure to CCl4 increased
mRNA levels of inﬂammatory mediators strongly linked to activation
of macrophages and stellate cells including Ccl2, Ccl4, Ccl5, Cd14,
Cxcl10, Icam1, Itgb2 and Timp1. Also, acute phase protein App,
Fig. 4. Increased oxidative stress in livers of CCl4-exposed c-Met deﬁcient livers. (A) The levels of TBARS, a byproduct of lipid peroxidation, were detected by the TBARS assay using
thiobarbituric acid as a reagent and expressed as nmol/mg protein. The data are presented as means±SD (n=3). (B) The ratios of reduced glutathione (GSH) to oxidized gluta-
thione (GSSG) determined by HPLC. The data are presented as means±SD (n=3). (C and D) Western blotting of whole cell lysates prepared from Metﬂ/ﬂ;Alb-Cre+/− and
Metwt/wt;Alb-Cre+/− livers using indicated antibodies. β-Actin served as a loading control. * Pb0.05; **Pb0.01.
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CD14, involved in the formation and transport of MHC class II protein,
as well as regulators of cell-to cell communication and adhesion
(Adam8, Icam1, Itgax, Itgb2, CD48), intracellular trafﬁcking and calci-
um ion channel formation (Annexin A2, CD93, CD97) were among
the genes with increased expression. Additionally, signaling associat-
ed with survival, cell death and stress response (App, Aqp2, Bax, Bcl3,
C1qa, Capn1, Cd14, Cdkn1a, Cyba, Cyﬁp2, Dnmt3a, Egr1, Fasn, Fgr, Hif1a,
Hspa5, Icam1, Lmo2, Ly86, Max, Ncf1, Ncf2, Ncf4, Pik3r1, Plg, Rcan1,
S100a11, Serpine1, Soat1, Tasp1, Timp1, Tnfaip8, Tnfrsf1b, Tyrobp,
Usp18, Xrcc4, Zfp36) as well as tissue remodeling and wound repair
(B4galt1, Col3a1, Col5a1, Itgb2, Mfap2, Pdfga, Plg, Serpine1) were affect-
ed by the loss of c-Met in hepatocytes. Consistently, genes essential
for hepatocyte function such as cholesterol and bile acid homeostasis
(Dhcr7, Fdps, Idi1, Sqle, Cyp8b1, Lipc, Pklr, Slc22a5, Slc22a7) and metab-
olism (Aldh6a1, Cyp17a1, Cyp2b10, Cyp2c55, Cyp2c68, Cyp2f2, Cyp2j5,
Cyp4a10, Cyp4f14) were downregulated in Metﬂ/ﬂ;Alb-Cre+/− hepa-
tocytes. However, CCl4 treatment increased mRNA levels of several
components of the superoxide-producing NADPH-oxidase, including
Ncf1, Ncf2, and Ncf4, supporting our earlier ﬁndings in c-Met-
deﬁcient hepatocytes [21].
Finally, to address broad transcriptional response to CCl4 exposure
we isolated RNA from liver samples at various time-points during the
injury phase (1 day, 1 week, 2 weeks, and 3 weeks) and performed
gene expression proﬁling using a 2-factor time course analysis taking
into consideration both genotype-speciﬁc and time dependent tran-
scriptional changes. A total of 680 genes including 147 upregulated
and 533 down-regulated genes, were differentially expressed
(FDRb0.05, ≥2-fold) in Metﬂ/ﬂ;Alb-Cre+/− livers during injury
phase (Supplemental Table S1). These genes were highly efﬁcient in
separating both genotypes as well as time points (Fig. 5C). Major as-
sociated signaling pathways were related to tissue remodeling, in-
ﬂammation, cell cycle, apoptosis as well as DNA damage andoxidative stress response (Fig. 5D). Among the dominant networks
and canonical pathways were proﬁbrotic signaling, such as TGF-β1,
as well as pathways related to inﬂammation, stress response and sur-
vival (Fig. 4C and D; Supplemental Fig. 4). We also found a compensa-
tory up-regulation of EGFR signaling supporting our previous work on
Metﬂ/ﬂ;Alb-Cre+/− mice [28]. Consistent with c-Met knockout pro-
ﬁbrotic phenotype, there was increased expression of markers for
HSC activation (Tgfβ1, Tgfbr3, Thy1,) and phagocyte/macrophage
function and survival (Cd68, C6, C1qc, Csf2ra, Fcer1g, Fpr2, Stat1,
Timd4, Bcl6, Tyrobp, Fger1g, Egfr1, etc.). Conversely, pathways related
to acute stress response (Alb, Apoh, Cfb, Hnrndk, Hrg, Il6st, Pik3r2,
Ptpn11, Rbb4, Tab1,Traf6), survival (NF-kB, Irak1 and 3, K-Ras, Pik3r2,
Tnfrsf11a), DNA damage and oxidative stress regulation (Rad9,
Rad52, Ercc4, Gsta1 and 2, Jun, Gclc, Prdxd2, Fxn) were progressively
down-regulated reﬂecting impaired regenerative capacity in the ab-
sence of c-Met signaling [9,10,27,38]. We also detected a signiﬁcant
reduction in the expression levels of several members of MAP-
kinase family (Mapk9, Mapk12, Mapk1ip1, Mapk3k7ip1) responsive
to growth factor and stress stimuli and genes which function to coor-
dinate S phase and cell division (Tk1, Rfc5, Skp2, Cup4a, Ncaph, Ccng2,
Csnk2a, Cdc6, cdk10, cdc123, cdc78, Chaf1a). In accordance with previ-
ous studies [23], we also found a prominent effect of c-Met deletion
on genes involved in cytoskeleton organization (Actb, Actl6a,
Tuba1a, Tuba8), chemotaxis and cell migration (Thy1, Cd207, Cd74,
Il6st, Tyrobp, Ifngr2, Tspan8, Serpina1a), intercellular communications
(Cdh5, Tjp1, Gjb2, Vezt) and adhesion (Vcam1, Cdh5, Cpxm1, Cul4a).
Furthermore, loss of c-Met decreased transcript levels of genes
encoding wide range of trans-membrane proteins which transport
various molecules across extra- and intracellular membranes, includ-
ing efﬂux transporters (Abca7, Abcd4, Abcc9, Abcf1, Atp2a3, Atp5a1,
Atp5e), inﬂux transporters of the solute carrier (SLC) family (Slc4a3,
Slc7a4, Slc7a6os, Slc11a1, Slc15a3, Slc16a9, Slc23a2, Slc27a5, Slc37a,
Slc39a13) as well as genes regulating trafﬁc of membrane proteins
Fig. 5.Microarray analysis reveals a broad impact of c-Met-deﬁciency on the critical signaling pathways associated with ﬁbrotic disease. (A) Unsupervised hierarchical cluster analyses of isolated hepatocytes at 1 week of injury phase. A total
of 406 differentially expressed genes were identiﬁed using Bootstrap t-test (P-valueb0.01) (B) Top signaling pathways in Metﬂ/ﬂ;Alb-Cre+/− hepatocytes as determined by GeneGo analysis. (C) Hierarchical cluster analysis during injury
phase (1 d, 1 week, 2 weeks, 3 weeks). A total of 680 differentially expressed genes in Metﬂ/ﬂ;Alb-Cre+/− livers were identiﬁed (FDR≤0.05; fold change ≥2). Note a clear separation of both genotypes and different time points. (D) Top
signaling pathways in Metﬂ/ﬂ;Alb-Cre+/− livers as determined by GeneGo analysis.
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Vapa, Cav1) [39]. Consistent with this, Metﬂ/ﬂ;Alb-Cre+/− mice trea-
ted with CCl4 also displayed down-regulation of several members of
DUB family of cytokine-regulated deubiquitinating enzymes (Usp1,
Usp2, Usp10, Usp14), important regulators of the diverse cellular pro-
cesses including receptor internalization and vesicle trafﬁcking
[40,41] as well as a range of G-protein coupled receptors, the major
sensors of outside molecules which function in intracellular signaling
(Gpr1, Gpr65, Gpr108, Gpr124, Gpr137, Gpr146) [42]. Expression levels
of S100a11, a member of the Ca(2+)-binding S100 protein family
thought to facilitate membrane vesicle-fusion events such as endocy-
tosis and membrane repair [43] as well as CAV1, the main structural
protein of caveolae involved in cholesterol homoeostasis, transcyto-
sis, and endocytosis [44] were also markedly decreased. Together
these data reveal the massive changes in cellular metabolism and mi-
croenvironment caused by the deletion of c-Met receptor in
hepatocytes.
4. Discussion
In this study, we used Metﬂ/ﬂ;Alb-Cre+/− mice and a model of
chronic CCl4-induced liver injury to investigate the molecular and cel-
lular mechanisms underlying the anti-ﬁbrotic activities of HGF/c-Met.
We provide evidence that genetic loss of c-Met in hepatocytes in-
duces a state of “organ stress” characterized by multi-factorial
changes both in parenchymal and non-parenchymal cell compart-
ments in the liver. These include reduced hepatocyte proliferation,
rapid pathological calciﬁcation of necrotic areas with impact on the
ability of macrophages to remove or sequester necrotic material,
and excessive activation of hepatic stellate cells, thereby aggravating
inﬂammation and ﬁbrosis. Transcriptome analysis revealed that loss
of c-Met receptor in hepatocytes caused a widespread deregulation
of critical signaling pathways associated with immune cell trafﬁcking,
oxidative stress and DNA damage response, in addition to prolifera-
tion and cell death. These ﬁndings establish a broad protective role
for c-Met signaling in hepatocytes against toxic liver damage leading
to development of ﬁbrotic disease.
There is extensive evidence for a mitogenic role of HGF/c-Met
[15,24,25,37]. We and others have conﬁrmed the central role of c-
Met in cell cycle initiation and progression in gene knockout studies
in rodents [9,38]. The extent of mito-inhibition varied in c-Met condi-
tional knockout mice expressing Cre-recombinase under the control
of a ubiquitously expressed interferon-inducible or hepatocyte-
speciﬁc Alb-Cre promoter [9,29,38] varied and was less severe in
Metﬂ/ﬂ;Alb-Cre mice most likely due to the adaptive up-regulation
of alternative survival and proliferating signaling [21,23,28]. Never-
theless, in both models a conditional c-met inactivation caused an in-
hibition of Erk1/2 activation and a subsequent suppression of cell
cycle regulators in a model of two-thirds partial hepatectomy. Consis-
tent with this, in Metﬂ/ﬂ;Alb-Cre ﬁbrotic livers we have detected a sig-
niﬁcant reduction in the expression levels of several members of MAP
kinase family (Mapk9, Mapk12, Mapk1ip1, Mapk3k7ip1) responsive to
growth factor and stress stimuli and genes which function to coordi-
nate S phase and cell division (Tk1, Rfc5, Skp2, Cup4a, Ncaph, Ccng2,
Csnk2a, Cdc6, cdk10, cdc123, cdc78, Chaf1a). A signiﬁcant number of
down-regulated genes encoded proteins controlling proper chromo-
some segregation (Sma3, Smc1a, Cep78), spindle integrity and spindle
checkpoint signaling (Spc24, Cspp1, Mad2l1bp, Anapc5) in line with
our earlier work which established a critical role for c-Met in control
of G2/M transcriptional program [38].
It is well known that the hepato-protective effects of HGF/c-Met
signaling can dramatically attenuate the process of liver ﬁbrosis by di-
rect inhibition of pro-ﬁbrotic molecules (e.g. TGF-β) as well as pro-
motion of ECM resolution [12,13,45]. In agreement with these data,
our results demonstrate that the absence of hepatocyte c-Met signal-
ing caused increased expression of pro-ﬁbrotic molecules, such asTGF-β (Fig. 4C, Supplemental Fig. 4B), in parallel with excessive
HSCs activation and ECM accumulation in Metﬂ/ﬂ;Alb-Cre+/− livers
challenged with CCl4 (Fig. 2). The TGF-β upregulation could contribute
at least in part to suppression of hepatocyte mitogenesis in Metﬂ/ﬂ;
Alb-Cre+/− ﬁbrotic livers.
Pathophysiologically, the outcome of liver injury depends on the
interactions between inﬂammatory cells (e.g. macrophages), non-
inﬂammatory cells (e.g. HSCs) and hepatocytes [1]. The primary deﬁ-
ciencies in c-Met deﬁcient livers involve repair impediment associat-
ed with hepatocyte damage, inﬂammation, and activation of matrix
producing HSCs (Figs. 1–3). Remarkably, DNA microarray analysis of
isolated hepatocytes during early ﬁbrotic response revealed that
loss of c-Met receptor caused a strong upregulation of chemotactic
cytokines and adhesion molecules (Fig. 5, A and B) suggesting a direct
parenchymal involvement in the production of factors associated
with immunological functions.
Consistent with c-Met knockout phenotype, among the overex-
pressed genes were several members of “CC” (CCL2, CCL4, and CCL5)
and “CXC” (CXCL10) families of chemokines as well as cell adhesion
molecules (e.g. ICAM-1) implicated in inﬂammatory cell trafﬁcking
into sites of injury and initiation of immunologic and inﬂammatory
reactions. Thus, CCL2, also known as monocyte chemoattractant pro-
tein 1 (MCP-1), expressed by both hepatocytes and macrophages, has
been shown to participate in macrophage fusion and foreign body
giant cell formation [46,47]. Noteworthy, the increased expression
of proinﬂammatory CCL5, known as RANTES, has been identiﬁed in
hepatocytes in response to inﬂammatory conditions including hepa-
tocellular steatosis [48]. Upregulation of RANTES was also found in
renal tubular epithelial cells during obstructive nephropathy al-
though no or little RANTES protein was observed in normal kidney
[49]. Signiﬁcantly, HGF gene therapy was capable of suppressing epi-
thelial RANTES expression in parallel with inhibition of inﬂammatory
cells inﬁltration [49,50].
Exposure to CCl4 also increased hepatic expression of CXCL10, an-
other important cytokine implicated in progression of liver ﬁbrosis
[51,52]. It has been shown that CXCL10 promoted liver ﬁbrosis by
preventing hepatic stellate cell inactivation by natural killer cells
[53]. These ﬁndings are in line with a recent study which related
the pro-ﬁbrotic effects of c-Met deﬁciency in hepatocytes to increased
survival of HSCs in a model of liver ﬁbrosis induced by bile duct liga-
tion [27].
Genotype and time-dependent transcriptome analysis of CCl4-
exposed livers conﬁrmed the wide-ranging impact of c-Met deﬁciency
on critical signaling pathways associated with ﬁbrotic disease (Fig. 5, C
and D). Among the top canonical pathways affected by the loss of hepa-
tocyte c-Met there were acute phase response signaling, production of
nitric oxide and ROS in macrophages, mitochondrial dysfunction,
PDGF signaling, interferon signaling, HGMB1 signaling, toll-like recep-
tor signaling along with NF-kB, IL-6, EGF, and TGF-β signaling (Figs. 4
and 5, Supplemental Fig. S4). Functional analysis of differentially
expressed genes in Metﬂ/ﬂ;Alb-Cre+/− livers treated with CCl4 also
revealed modulation of several members of G-protein coupled recep-
tors (GPCRs) implicated in regulation of immune system and inﬂamma-
tion, reorganization of cytoskeletal network and intercellular
communication between cells (e.g. Actb, Tjp1, Gjb2), deregulation of a
range of receptors (e.g. GPCRs, Tnfrs8, Tnfrs10b,Tnfrsf11a, Ifngr2, Il3ra,
Fcgr4, Ppargc1a, etc.) and membrane transporters, including members
of ATP-binding cassette and solute carrier families. The loss of c-Met
also affected the genes involved in ubiquitin-mediated signaling (e.g.
Usp1, 2, 10 and 14, Sumo1) known to act in transcriptional regulation,
nuclear transport, and protein stability [40,41].
In the setting of c-Met deﬁciency, the mechanistic signiﬁcance of
prooxidant-mediated hepatic ﬁbrosis may be particularly relevant in
potentially initiating a cascade of pro-ﬁbrotic events. Previously, we
have demonstrated that unchallenged c-Met conditional livers exhibit
increased oxidative damage and reduced levels of GSH which were
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tecting against oxidative and xenobiotic stress, including Nrf2 and NF-
κB [21,28]. However, when subjected to a chronic treatment with
CCl4, Metﬂ/ﬂ;Alb-Cre+/− livers were not capable of maintaining an ade-
quate pro-survival signaling and displayed a strong down-regulation of
the NF-κB and Nrf2 dependent genes (Fig. 4C, Supplemental Fig. 4C).
Consistent with these ﬁndings, CCl4-exposed c-Met knockout livers dis-
played a more signiﬁcant elevation of lipid peroxidation products,
known as strong inducers of HSC activation [54], during early ﬁbrotic
response relative to controlmice (Figs. 4A). Theseﬁndings show that in-
creased oxidative stress is one of the hallmark features of the hepato-
cyte c-Met deﬁciency which may aggravate CCl4 induced liver ﬁbrosis.
However, the loss of c-Met signaling in the context of chronic CCl4
liver injury caused a plethora of diverse cellular andmolecular changes,
including aberrant tissue remodeling, disruption of a coordinated
wound-healing response and reduced stress resistance, exceeding the
sole secondary effects ascribed to oxidative stress.
Collectively, these ﬁndings provide mechanistic explanation for
the high susceptibility of Metﬂ/ﬂ;Alb-Cre+/− mice to chemically in-
duced hepatic ﬁbrosis. The proﬁbrotic effects of c-Met deﬁciency
were mediated by activation of the major proinﬂammatory genes in
addition to increased oxidative stress and lack of compensatory re-
generation. Although more work is required to determine the exact
contribution of each of these factors, the study establishes a key pro-
tective role for intact c-Met signaling in the maintenance of structural
integrity and adaptive plasticity of the liver under adverse conditions
and strongly supports current efforts directed at modulating the HGF/
c-Met signaling pathway in therapeutic settings [55].
Supplementary materials related to this article can be found on-
line at doi:10.1016/j.bbadis.2012.02.012.
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